Hexamethylmelamine for the treatment of ovarian cancer—The Mount Sinai experience
- 31 March 1991
- journal article
- clinical trial
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 18, 57-65
- https://doi.org/10.1016/0305-7372(91)90025-u
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Schedule and dosage modification of a cyclophosphamide, hexamethylmelamine, doxorubicin, cisplatin combination chemotherapy regimen for refractory ovarian cancerEuropean Journal of Cancer and Clinical Oncology, 1989
- Role of Hexamethylmelamine in the Treatment of Ovarian Cancer: Where is the Needle in the Haystack?JNCI Journal of the National Cancer Institute, 1988
- RANDOMISED TRIAL COMPARING TWO COMBINATION CHEMOTHERAPY REGIMENS (HEXA-CAF VS CHAP-5) IN ADVANCED OVARIAN CARCINOMAThe Lancet, 1984
- Cisplatin regimens and improved prognosis of patients with poorly differentiated ovarian cancerAmerican Journal of Obstetrics and Gynecology, 1983
- Treatment of chemotherapy-resistant advanced ovarian cancer with a combination of cyclophosphamide, hexamethylmelamine, adriamycin, and cis-diamminedichloroplatinum (CHAP)Gynecologic Oncology, 1981
- High-dose platinum for the treatment of refractory ovarian cancerGynecologic Oncology, 1981
- Improved chemotherapy for ovarian cancer with cis-diamminedichloroplatinum and adriamycinCancer, 1981
- Chemotherapy of Recurrent Ovarian Carcinoma with cis-Dichlorodiammine Platinum II and AdriamycinObstetrics & Gynecology, 1980